<DOC>
	<DOCNO>NCT00113529</DOCNO>
	<brief_summary>To assess maximum tolerate dose overall safety tolerability sunitinib [ SU011248 ] administer combination gefitinib ( Iressa ) treatment patient metastatic renal cell carcinoma ( Phase 1 ) . To assess antitumor activity combination gefitinib sunitinib ( Phase 2 ) .</brief_summary>
	<brief_title>Study Of SU011248 Plus Gefitinib ( Iressa ) In Patients With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically confirm renal cell carcinoma metastases Evidence unidimensionally measurable disease Failure 1 prior immunotherapy prior systemic therapy metastatic RCC RCC without clear ( conventional ) cell component History know brain metastasis Uncontrolled hypertension significant cardiac event within 12 month prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>